Clinical Trials on HCV (Genotype 1)

Total 14432 results

Bristol-Myers Squibb

Completed

Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects

HCV (Genotype 1)

United States, Puerto Rico
University of Southern Denmark
Odense University Hospital

Terminated

Development of Cocktail for Measuring the Activity of Important Cytochrome P450 Enzymes

Cytochrome P450 Phenotype and Genotype Metrics

Denmark
Bispebjerg Hospital
University of Copenhagen; Duke University; The Ministry of Science, Technology... and other collaborators

Completed

Metabolism of Methylphenidate and Enalapril Based on CES1 Genotype

Carboxylesterase 1 (CES1) Genotype | CES1 Activity

Denmark
Bispebjerg Hospital
University of Copenhagen; Duke University; The Ministry of Science, Technology... and other collaborators

Completed

Impact of CES1 Genotype on Metabolism of Methylphenidate

Carboxylesterase 1 (CES1) Genotype | CES1 Activity

Denmark
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.

Completed

A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients

Cirrhosis | Chronic Hepatics C Virus (HCV) Genotype 1 | Non-Cirrhotic | Treatment naïve

China
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
Peking University People's Hospital

Completed

To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients

Cirrhosis | Chronic Hepatics C Virus (HCV) Genotype 1 | Non-Cirrhotic | Treatment naïve

China
Gilead Sciences

Completed

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection

Chronic Genotype 4 HCV | Chronic Genotype 5 HCV

France
Biohaven Pharmaceuticals, Inc.

Active, not recruiting

Trial in Adult Subjects With Spinocerebellar Ataxia

Spinocerebellar Ataxias | Spinocerebellar Ataxia Genotype Type 1 | Spinocerebellar Ataxia Genotype Type 2 | Spinocerebellar Ataxia Genotype Type 3 | Spinocerebellar Ataxia Genotype Type 6 | Spinocerebellar Ataxia Genotype Type 7 | Spinocerebellar Ataxia Genotype Type 8 | Spinocerebellar Ataxia Genotype...

United States
Merck Sharp & Dohme LLC

Completed

Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336) (VIDA)

Hepatitis C, Chronic | Genotype 1 | HCV-1
Dartmouth-Hitchcock Medical Center

Completed

HSV Oral Reactivation in Children

HIV | HSV-1

Tanzania
Chinese Academy of Sciences
LanZhou University

Completed

Cytochrome P450 2C19 Variant is Related to Pharmacokinetics of Glipizide Extended Release Tablet in Chinese Subjects

Pharmacokinetic | Genotype

China
University College London Hospitals

Completed

Analysis of the Duration of Combination Therapy That is Necessary for HCV Genotype 1 Eradication

Chronic Hepatitis C, HCV Genotype 1

United Kingdom
University of Alabama at Birmingham
National Institutes of Health (NIH); Mereo BioPharma

Completed

Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency (ATALANTa)

Emphysema or COPD | Alpha-1 Antitrypsin Deficiency (AATD) | Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations

United States
Assistance Publique - Hôpitaux de Paris
Gilead Sciences

Terminated

HCV, HBV, HIV Testing During Consultation With Anesthesiologist (SAHARA)

Hiv | HBV | HCV

France
Sequenom, Inc.
NAFTNet

Completed

A Noninvasive Test for Fetal RHD Genotype (NAFTnet RHD)

Rhesus D Genotype

United States, Canada
Sequenom, Inc.
Sequenom Center for Molecular Medicine

Completed

Evaluation of a Noninvasive Fetal RHD Genotyping Test (IRIS)

Rhesus D Genotype

United States
Matthias Schwab

Completed

Open Label Study for the Functional Characterization of Drug Metabolism and Transport (IKP243)

Genotype-related Drug Metabolism

Germany
California Pacific Medical Center Research Institute
Children's Mercy Hospital Kansas City

Withdrawn

The Impact of Genetic Variation in CYP2D6 on the Pharmacokinetics and Pharmacodynamics of Methamphetamine

Methamphetamine Metabolism, CYP2D6 Genotype

United States
Samsung Medical Center

Unknown

Isoniazid Dosage Prediction Model Development

NAT2 Genotype

Korea, Republic of
National Research Council, Spain
IMDEA Food; CEIP (primary school) Jara Carrillo (Alcantarilla, Murcia, Spain); IES (secondary school) Alcántara (Alcantarilla, Murcia, Spain)

Completed

Genotype, Metabotype and Diet in a Cohort of Children and Adolescents From the Southeast of Spain. (PolyMicroBio)

Genotype, Metabotype and Dietary Habits

Spain
Inje University

Completed

STUDY The Effect of HNF-4A G60D Variant on the In VIVO CYP2D6 Activity By Tolterodine Pharmacokinetic Study (HNF4a)

Healthy Subjects | Genotype Guided(HNF4a)
AbbVie (prior sponsor, Abbott)

Completed

ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients

Chronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV)

United States, Australia, Canada, France, Germany, New Zealand, Puerto Rico, Spain, United Kingdom
Fred Hutchinson Cancer Center
Institute for the Development of Africa

Completed

Usage of Acyclovir for Suppression of HIV-1 and HSV-2 Coinfected Persons in Cameroon

HIV Infections | HIV-1 and HSV-2 Coinfection

Cameroon
National Taiwan University Hospital

Not yet recruiting

UGT1A1 Genotyping in Taiwanese Cancer Patients

The Influence of the UGT1A1 Genotype
AbbVie

Completed

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults

Chronic Hepatitis C Virus (HCV Infection Genotype 1)
AbbVie (prior sponsor, Abbott)

Completed

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 (Champion2)

Hepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1

United States, Puerto Rico
AbbVie (prior sponsor, Abbott)

Completed

A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)

Hepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1

United States
University of Southern Denmark

Completed

Impact of CYP2C19*17 on the Pharmacokinetics of Proguanil and Clopidogrel

CYP2C19 Genotypes

Denmark
GlaxoSmithKline

Completed

Serological Response to Porcine Circovirus Type 1 (PCV-1) and PCV-1 DNA in Stools of Infants Following Administration of Rotarix™

Rotavirus Infection | Evidence of PCV-1 Replication and/or Immune Response to the PCV-1 in HRV Vaccinated Infants
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Algeria, Australia, Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Spain, Switzerland, Turkey, Austria, Ireland and more
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-II)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

United States
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Rennes University Hospital

Completed

Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (BocepreVIH)

HIV-1 Infection | HCV Coinfection

France
Northwell Health

Terminated

1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

High Risk MC4R Genotype | Low Risk MC4R Genotype | One Week or Less Antipsychotic Lifetime Exposure

United States
Trek Therapeutics, PBC

Completed

A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection

Chronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C Viral Infection

United States, New Zealand
Gilead Sciences

Completed

GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection

Chronic Genotype 1a or 1b HCV Infection

United States, Canada, Puerto Rico
Presidio Pharmaceuticals, Inc.

Completed

A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1

Chronic Genotype 1 Hepatitis C Virus Infection

United Kingdom, Denmark, United States
Indiana University
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Evaluate Pharmacokinetics and Safety of Slow Release DHEA (DHEA)

Asthma | Genotype

United States
Novartis

Completed

Evaluation of HIV-1, HCV and HBV Blood Screening Tests With Human Blood Donor Specimens

Screening for the Presence of HIV-1, RNA and HBV DNA in Blood Donations

Taiwan
University of Nebraska

Completed

Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics

Genotype 1 Hepatitis C Virus

United States
Idera Pharmaceuticals, Inc.

Completed

Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients

Hepatitis C, Treatment Naïve, Genotype 1 Patients

France
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

Hepatitis C, Genotype 1

United States, Australia, France, Germany, Spain, Canada, Puerto Rico, Argentina, Brazil, Russian Federation, United Kingdom, Italy, Belgium
GlaxoSmithKline

Completed

Assessment of the Serologic Response to Porcine Circovirus Type 1 (PCV-1) in the Serum of Infants and Toddlers, Following Administration of IPV (Inactivated Poliovirus Vaccine)-Containing Vaccines

Presence of Materials From PCV-1
Dr.Waleed Samir

Unknown

Impact of IL-28B rs12979860 and rs4803217 Gene Polymorphisms Associated With miRNAs Deregulation on HCV-related Hepatocellular Carcinoma

HCV Infection ( Genotype 4)

Egypt
ANRS, Emerging Infectious Diseases
Institut National de la Santé Et de la Recherche Médicale, France; University... and other collaborators

Completed

Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention (PROMISE-EPI)

HIV-1

Burkina Faso, Zambia
Hospital Universitari Vall d'Hebron Research Institute
Gilead Sciences

Completed

Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla

HIV-1

Spain
Hospital Universitari Vall d'Hebron Research Institute
University Hospital, Ghent; IrsiCaixa

Completed

HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen

HIV-1

Spain
Gilead Sciences

Completed

Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada (RECOMB)

HIV-1

Spain
University of Aarhus
Aarhus University Hospital Skejby; Bandim Health Project; Abbott; Ministry of Health...

Completed

PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial (PIONA)

HIV-1

Guinea-Bissau
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

HIV-1

United States, France, Spain, Portugal, Canada, United Kingdom, South Africa, Argentina, Brazil, Puerto Rico, Thailand, Netherlands, Romania
Tibotec Pharmaceuticals, Ireland

Completed

An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).

HIV-1

United States, Canada, France, Belgium, Germany, Spain, Argentina, Chile, Panama, Brazil, Puerto Rico, Thailand, Mexico, Australia

Clinical Trials on HCV (Genotype 1)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations